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Abstract
Objective: To evaluate the frequency of infectious complications in children with sickle 
cell disease (SCD) after surgical splenectomy for acute splenic sequestration crisis.
Methods: Retrospective cohort of children with SCD who were born after 2002 and were 
regularly monitored until July 2013. Patients were divided into two groups: cases (chil-
dren with SCD who underwent surgical splenectomy after an episode of splenic seques-
tration) and controls (children with SCD who did not have splenic sequestration and 
surgical procedures), in order to compare the frequency of invasive infections (sepsis, 
meningitis, bacteremia with positive blood cultures, acute chest syndrome and/or pneu-
monia) by data collected from medical records. Data were analyzed by descriptive sta-
tistical analysis.
Results: 44 patients were included in the case group. The mean age at the time of sple-
nectomy was 2.6 years (1-6.9 years) and the mean postoperative length of follow-up was 
6.1 years (3.8-9.9 years). The control group consisted of 69 patients with a mean age at 
the initial follow-up visit of 5.6 months (1-49 months) and a mean length of follow-up 
of 7.2 years (4-10.3 years).All children received pneumococcal conjugate vaccine. No 
significant difference was observed between groups in relation to infections during the 
follow-up.
Conclusions: Surgical splenectomy in children with sickle cell disease that had splenic 
sequestration did not affect the frequency of infectious complications during 6 years of 
clinical follow-up.
© 2015 Sociedade de Pediatria de São Paulo. Published by Elsevier Editora Ltda. All rights 
reserved.
DOI of original article: http://dx.doi.org/10.1016/j.rpped.2014.09.006
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Complicações infecciosas em crianças com doença falciforme após esplenectomia 
 cirúrgica
Resumo
Objetivo: Avaliar a frequência de complicações infecciosas em pacientes portadores de 
doença falciforme (DF) submetidos à esplenectomia cirúrgica, após episódio de sequestro 
esplênico (SE).
Métodos: Coorte retrospectiva de crianças com DF que nasceram após 2002 e que esta-
vam em acompanhamento regular até julho de 2013. Os pacientes foram divididos em 
dois grupos,casos (constituído pelas crianças com DF que fizeram esplenectomia cirúrgica 
após sequestro esplênico) e controles (crianças com DF que não tiveram SE e não foram 
submetidas ao procedimento), a fim de comparar a frequência de infecções invasivas 
(sepse, meningite, bacteremia com hemocultura positiva, síndrome torácica aguda e/
ou pneumonia) por meio de informações obtidas do prontuário. A análise estatística foi 
descritiva.
Resultados: Foram avaliados 44 pacientes com idade média no momento da esplenecto-
mia de 2,6 anos (1-6,9 anos) e com tempo médio de seguimento após esplenectomia de 
6,1 anos (3,8-9,9 anos). O grupo controle foi formado por 69 pacientes com idade média 
do início do seguimento de 5,6 meses (1-49 meses) e tempo de acompanhamento médio 
de 7,2 anos (4-10,3 anos). Todos receberam a vacina pneumocócica conjugada. Não foi 
observada diferença significativa entre os grupos em relação aos processos infecciosos 
durante o período de seguimento.
Conclusões: A esplenectomia cirúrgica nas crianças com doença falciforme e que so-
freram sequestro esplênico não se associou ao aumento na frequência de complicações 
infecciosas após seis anos de acompanhamento clínico.
© 2015 Sociedade de Pediatria de São Paulo. Publicado por Elsevier Editora Ltda. Todos os 
direitos reservados.
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Introduction
Sickle-cell disease (SCD) is a type of hemolytic anemia 
caused by hemoglobinopathy that, due to the substitution 
of valine for glutamic acid at the sixth position of the beta 
globin chain, leads to the formation of an abnormal hemo-
globin, called “S” hemoglobin (HbS).1 SCD comprises sick-
le-cell anemia (SCA) and the associations that occur when 
the hemoglobin S gene is associated with the gene of other 
hemoglobinopathies, such as SC hemoglobinopathy (HbSC) 
and HbS-beta thalassemia (HbSb).1
Among the complications of SCD, splenic sequestration 
(SS) affects 7.5% to 30% of patients, usually between 3 
months and 5 years of age, being the second leading cause 
of death in the first decade of life.1,2 The mortality rate for 
SS crisis can reach 12% and may occur in more than 50% of 
patients.1,3,4 Treatment should be immediate, aiming to 
restore blood volume through transfusion of red blood 
cells.1 The prevention of SS recurrence can be performed 
through periodic transfusions, chronically, or via splenecto-
my.1,5-8
The effectiveness of chronic transfusion in preventing 
recurrence is not well established. A study showed that the 
SS crisis occurs in spite of the reduction of hemoglobin S 
(Hb) to less than 30%, with the risk of recurrence being 
similar in patients receiving chronic transfusions compared 
to the ones who remained under clinical observation.6 
However, randomized studies are needed to confirm these 
data.2 Brousse et al. found that the risk of recurrence was 
higher when the first SS episode occurred before two years 
of age and concluded that a more aggressive preventive 
treatment should be carried out at this age range.9
The performance of a splenectomy early in life is always 
debatable due to the increased risk of infection by encap-
sulated bacteria.10 However, it should be considered that 
children with sickle-cell disease show splenic hypofunction 
since the first months of life,11 and that advances in the 
prevention of these infections through prophylaxis with 
penicillin and conjugate vaccines have decreased the 
risk.12,13
Therefore, the aim of this study was to evaluate the fre-
quency of infectious complications after surgical splenecto-
my in children with SCD.
Method
This is a retrospective cohort study carried out with data 
obtained from medical records of patients followed in a 
Pediatric Hematology service. The study population (PG) 
consisted of children with SCD born from 2002 to 2007, sub-
mitted to surgical splenectomy after the first episode of 
splenic sequestration between January 2003 and February 
2009 and who had regular follow-up until July 2013. After 
the first episode of splenic sequestration, these patients 
were submitted to a regimen of chronic red blood cell trans-
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fusion every four weeks, until the immunization schedule 
was complete, with the 7-valent pneumococcal vaccine 
given between 12 and 15 months of age and elective sple-
nectomy being indicated after this prerequisite. The control 
group (CG) consisted of children with SCD born between 
2002 and 2009 who did not have splenic sequestration, were 
not submitted to surgical splenectomy, and were undergoing 
regular follow-up at our service until July 2013.
Both groups received penicillin prophylactically, from 
diagnosis to at least 5 years of age, until they received the 
booster of the 23-valent pneumococcal polysaccharide vac-
cine. All patients had adequate and complete immunization 
schedules for the age regarding the vaccines: 7-valent pneu-
mococcal conjugate, meningococcal, anti-Hemophilus, and 
23-valent pneumococcal polysaccharide vaccine. All patients 
received the conjugate vaccine during the first year of life.
Clinical and laboratory data were obtained from medical 
records that included patients’ routine consultations at the 
clinic, taking into account the information given by par-
ents/tutors, hospital discharge summary, and test results. 
The data obtained were: genotype, age at onset of the first 
splenic sequestration episode, infectious complications 
(bacterial meningitis, sepsis, positive blood culture [BC], 
acute chest syndrome [ACS]/pneumonia). For The PG, in 
addition to the previous data, the age at the time of sple-
nectomy and time of follow-up after splenectomy were col-
lected.
The analysis of the results took variable type into consid-
eration, in case of unrelated samples. Descriptive analysis of 
the profile of the studied patients was performed. Fisher’s 
exact test was used for the analysis of categorical variables 
to demonstrate the significance of differences between the 
PG and the CG in relation to infectious complications. The 
descriptive level of p<0.05 was considered statistically sig-
nificant by rejecting the hypothesis of equality.
The study was approved by the Institutional Review 
Board of Universidade Federal de São Paulo.
Results
Of the 53 patients submitted to surgical splenectomy during 
the period of study enrollment, 44 (83%) SCD patients who 
underwent surgical splenectomy and were submitted to reg-
ular follow-up throughout the study period were included. 
The children’s age at the splenic sequestration episode 
ranged from 2 to 79 months (mean 21.2±16.5 months), and 
21 (70.5%) patients were younger than 2 years when the first 
episode of splenic sequestration occurred, and the age when 
they underwent splenectomy was 1 to 6.9 years (mean 
2.6±1.3 years). As for the genotype, 39 (88.6%) patients were 
Hb SS carriers, 4 (9.1%) were Hb Sβ0 thalassemia carriers, 
and 1 (2.3%) was a Hb SC carrier. The time of follow-up after 
splenectomy was 3.8 to 9.9 years (mean 6.1±1.6 years).
As for the CG, data from 69 patients undergoing regular 
follow-up were assessed; the age at the start of follow-up 
was 1 to 49 months (mean 5.6±9.2 months), and the dura-
tion of follow-up was 4-10.3 years (mean 7.2±1.9 years). In 
relation to genotype, 57 (82.6%) patients were Hb SS carri-
ers, 1 (1.4%) was a Hb Sb0 thalassemia carrier, and 11 (16%) 
were Hb SC carriers.
Table 1 shows the infectious complications in children 
with sickle-cell disease after surgical splenectomy and in 
children from the control group. No difference was observed 
between the PG and CG in relation to the infectious pro-
cesses during follow-up of these patients.
The infectious agents isolated in blood cultures in the PG 
were Salmonella spp (1 patient) and Klebsiella spp 
(1 patient), and in the CG were Escherichia coli (1 patient), 
S. pneumoniae (1 patient), and Klebsiella spp (1 patient).
Discussion
Several studies, as well as the present one, verified that 
splenic sequestration is more common in children younger 
than 2 years of age,3-5 with this age range being the one 
during which infections by encapsulated bacteria, especial-
ly Streptococcus pneumoniae, are more prevalent.14 The 
spleen plays an important role in the defense against these 
microorganisms, and the removal of this organ is associated 
with increased risk of infection11; thus, the indication for 
splenectomy in this age group should always be judicious.
Patients with sickle-cell anemia have splenic hypofunc-
tion since the first months of life and undergo self-splenec-
tomy at around 5 years of age,1,11 therefore the risk of 
infection is increased. Thus, these patients receive prophy-
laxis with penicillin since the age of 2 months15 and vac-
cines against encapsulated organisms, such as pneumococ-
cus and Haemophilus.12 The introduction of prophylaxis and 
vaccines, especially of conjugate vaccines, led to a signifi-
cant reduction in mortality due to infectious processes in 
these patients, and in spite of continued need for surveil-
lance and concern about the emergence of pneumococcal 
strains resistant to penicillin or invasive strains not covered 
by the vaccine, these preventive measures have been 
effective so far.12,13 Thus, it can be considered that patients 
with SCD, surgically splenectomized or not, are at increased 
risk for infection, but it is of concern whether the complete 
loss of splenic function early in life after surgical splenec-
tomy could increase the number of infectious complica-
tions.
Table 1 Infectious complications in children with sickle-cell 
disease after surgical splenectomy and children from the 
control group.
Groups (n=113) p-value*
Splenectomized 
(n=44)
Controls 
(n=69)
Positive BC for 
S. pneumoniae
0 1 (1.4%) NA
Positive BC for 
other bacteria
2 (4.5%) 3 (4.3%) 1.0
Sepsis 1 (2.3%) 0 NA
Meningitis 0 1 (1.4%) NA
ACS/pneumonia 33 (75%) 51 (74%) 1.0
BC, blood culture; ACS, acute chest syndrome; NA, data not 
analyzed.
*Fisher’s exact Test.
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A case series study of sickle-cell patients splenectomized 
from 1988 to 1992 showed no statistical difference in the 
incidence of sepsis before and after splenectomy,16 a result 
similar to that observed by Kalpatthi et al., who performed 
a retrospective cohort study of 58 patients and also found 
no difference in the risk of invasive infections before and 
after surgery.17 The risk of invasive infection, especially 
pneumococcal, in children with sickle-cell disease is the 
highest in the first 3 years of life and significantly decreas-
es after the age of 5.18,19 Therefore, following the same 
patient before and after surgical splenectomy leads to a 
bias, considering that invasive infections will decrease over 
the years, even in splenectomized patients, as observed by 
the abovementioned studies.16,17
Our study compared the frequency of invasive infection 
among sickle-cell patients at the same age range, with the 
same time of follow-up, with and without surgical splenec-
tomy, similarly to the study by Wright et al., who also used 
a control group in their retrospective cohort.20 There was 
no difference regarding infection rates between the groups 
in both studies.
The incidence of ACS in patients with sickle-cell disease 
is approximately 30%.2,21 In the present study, approximate-
ly 75% of patients had annotations in their medical files 
about the previous occurrence of ACS/pneumonia. This is 
probably due to the different criteria used in emergency 
departments to characterize such complication. This bias 
occurred homogeneously in both groups.
The main study limitation was obtaining retrospective 
data from medical records, which are subject to recall bias 
and thus prevent the establishment of uniform criteria to 
define the diagnosis of infectious complications. Prospective 
studies are necessary to better assess this issue and confirm 
the results observed to date.
It can be concluded that the indication for surgical sple-
nectomy in children with sickle-cell disease that had splen-
ic sequestration was not associated with an increased fre-
quency of invasive infectious processes during the follow-up 
period.
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